SKYCovione, South Korea's No. 1 COVID-19 vaccine developed by SK Bioscience, has been confirmed to have an additional vaccination effect in the cross-neutralization of the omicron mutation virus (BA.1, BA.5).

Korea National Institute of Health (Director Kwon Joon-wook) announced on the 2nd that it has confirmed cross-neutralizing anti-bibody testers for the domestic epidemic omicron mutation virus after additional vaccination with SKYCovione. The National Institute of Health conducted a phase 3 clinical trial sample analysis required for item approval of SKYCovione, the first COVID-19 vaccine in Korea developed by SK Bioscience, and a cross-nutritionalizing ability analysis on delta mutant viruses and o